• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Galapagos and development partner Gilead set out to explore filgotinib applicability even futher. This time, the molecule's anti-inflammatory capacity will be tested in cutaneous lupus erythematosus.

Kiadis Pharma asks permission to the EMA to bring its lead product to the market. ATIR101™ protects blood cancer patients receiving a stem cell transplant from vulnerability to infections and disease relapse.

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Galapagos and development partner Gilead set out to explore filgotinib applicability even futher. This time, the molecule's anti-inflammatory capacity will be tested in cutaneous lupus erythematosus.

Kiadis Pharma asks permission to the EMA to bring its lead product to the market. ATIR101™ protects blood cancer patients receiving a stem cell transplant from vulnerability to infections and disease relapse.